Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01JLO
|
|||
| Former ID |
DIB010336
|
|||
| Drug Name |
Tat-NR2B9c
|
|||
| Synonyms |
NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Cerebrovascular ischaemia [ICD-11: 8B1Z; ICD-10: I67.8; ICD-9: 434.91] | Phase 3 | [1], [2], [3] | |
| Stroke [ICD-11: 8B20; ICD-10: I64] | Phase 3 | [4], [5] | ||
| Company |
Nono inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C105H188N42O30
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)N
|
|||
| InChI |
1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1
|
|||
| InChIKey |
XWQVQFBTSBCKLI-FKXNDIMNSA-N
|
|||
| CAS Number |
CAS 500992-11-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Presynaptic density protein 95 (DLG4) | Target Info | Inhibitor | [1], [2], [3] |
| KEGG Pathway | Hippo signaling pathway | |||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Cocaine addiction | ||||
| Panther Pathway | Huntington disease | |||
| Pathway Interaction Database | ErbB4 signaling events | |||
| Reactome | Trafficking of AMPA receptors | |||
| Unblocking of NMDA receptor, glutamate binding and activation | ||||
| CREB phosphorylation through the activation of CaMKII | ||||
| Ras activation uopn Ca2+ infux through NMDA receptor | ||||
| RHO GTPases activate CIT | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. | |||
| REF 2 | Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995 Sep 22;269(5231):1737-40. | |||
| REF 3 | Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999 Jun 11;284(5421):1845-8. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.